Meharry Medical College

PROPEL and Southern Company Announce Launch of Inaugural HBCU-Focused Cybersecurity Consortium

Retrieved on: 
Wednesday, April 24, 2024

ATLANTA, April 24, 2024 /PRNewswire/ -- PROPEL, a first-of-its-kind innovation hub for 2-year and 4-year Historically Black Colleges and Universities (HBCUs), announces the launch of a pioneering cybersecurity consortium. The PROPEL HBCU Cybersecurity Consortium (HCC), created in partnership with Southern Company, was founded on the principles of collaboration, leadership, innovation and foresight.  

Key Points: 
  • Consortium advances future-focused workforce opportunities, unlocks cyber career pathways
    ATLANTA, April 24, 2024 /PRNewswire/ -- PROPEL, a first-of-its-kind innovation hub for 2-year and 4-year Historically Black Colleges and Universities (HBCUs), announces the launch of a pioneering cybersecurity consortium.
  • The PROPEL HBCU Cybersecurity Consortium (HCC), created in partnership with Southern Company, was founded on the principles of collaboration, leadership, innovation and foresight.
  • "PROPEL's consortium will set a benchmark for developing a future workforce that is well equipped to address and solve the cybersecurity needs of today and tomorrow," said chairman, president and CEO of Southern Company Chris Womack.
  • PROPEL is proud to launch HCC's first two programs both aimed at elevating HBCU faculty and student expertise and skills in cybersecurity.

NUTEX HEALTH ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

Retrieved on: 
Monday, April 22, 2024

They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment.

Key Points: 
  • They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment.
  • The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market.
  • Dr. Spears is board certified in Emergency Medicine by the American Board of Emergency Medicine and is a Fellow of the American College of Emergency Physicians.
  • Nutex Health is a leader in this micro hospital sector and I'm glad to be a part of the Company," said Dr. Spears.

Dr. Kimberlee Etheridge named RISE's 2024 Health Care Hero

Retrieved on: 
Wednesday, April 17, 2024

NEW ORLEANS, April 17, 2024 /PRNewswire/ -- RISE is pleased to announce that Dr. Kimberlee Etheridge, primary care provider and assistant professor, Meharry Medical College; sr. VP health equity and diversity initiatives, ASTHO, is this year's winner of the RISE Health Care Hero Award.

Key Points: 
  • Dr. Etheridge received the RISE Health Care Hero Award on Wednesday, April 17 at The RISE Summit on Social Determinants of Health in New Orleans.
  • NEW ORLEANS, April 17, 2024 /PRNewswire/ -- RISE is pleased to announce that Dr. Kimberlee Etheridge, primary care provider and assistant professor, Meharry Medical College; sr. VP health equity and diversity initiatives, ASTHO, is this year's winner of the RISE Health Care Hero Award.
  • The Health Care Hero Award is a prestigious award presented at The RISE Summit on Social Determinants of Health that acknowledges an individual's effort to make a significant impact on the lives of underserved populations through health care and/or social services interventions, and through superior example of the RISE mission to promote health equity among all patients.
  • The award will be presented at The RISE Summit on Social Determinants of Health.

RISE announces finalists for 2024 Health Care Hero Award

Retrieved on: 
Saturday, March 16, 2024

NEW ORLEANS, March 16, 2024 /PRNewswire/ -- RISE is pleased to announce the finalists for the 2024 RISE Health Care Hero Award. The prestigious honor, presented annually at The RISE Summit on Social Determinants of Health, acknowledges an individual's effort to make a significant impact on the lives of underserved populations through health care and/or social services interventions, and through superior example of the RISE mission to promote health equity among all patients.

Key Points: 
  • RISE has narrowed the impressive candidate pool of nearly 60 nominations to the top five finalists.
  • NEW ORLEANS, March 16, 2024 /PRNewswire/ -- RISE is pleased to announce the finalists for the 2024 RISE Health Care Hero Award.
  • The prestigious honor, presented annually at The RISE Summit on Social Determinants of Health, acknowledges an individual's effort to make a significant impact on the lives of underserved populations through health care and/or social services interventions, and through superior example of the RISE mission to promote health equity among all patients.
  • The 2024 award recipient will be announced at The RISE Summit on Social Determinants of Health in New Orleans on Tuesday, April 16, the second day of the three-day conference.

Henry Schein, National Dental Association and Schattner Foundation Present Student Mentoring Program for Aspiring Dental Professionals

Retrieved on: 
Wednesday, February 21, 2024

Henry Schein, Inc. (Nasdaq: HSIC), National Dental Association (NDA), and Schattner Foundation are pleased to partner and present the S.M.I.L.E.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC), National Dental Association (NDA), and Schattner Foundation are pleased to partner and present the S.M.I.L.E.
  • This innovative public-private partnership is designed to mentor and support aspiring healthcare professionals and enhance inclusivity within the dental field.
  • Joining Henry Schein, the NDA, and Schattner Foundation in presenting the 2024 program are the Hispanic Dental Association, the Society of American Indian Dentists, Meharry Medical College School of Dentistry, and the A.T.
  • The program was made possible by a generous grant from the Schattner Foundation and the support of other professional organizations.

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Retrieved on: 
Wednesday, February 7, 2024

AUSTIN, Texas, Feb. 7, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the expansion of its nonclinical programs into new indications through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators to study TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The new indications being evaluated include ALK-positive lung cancer and other additional programs that are not disclosed at this time.

Key Points: 
  • The new indications being evaluated include ALK-positive lung cancer and other additional programs that are not disclosed at this time.
  • "Research indicates that the TUSC2 gene used in REQORSA may benefit many types of cancers and potentially the treatment of other diseases.
  • Research collaborators at the Rogel Cancer Center's Judith Tam ALK Lung Cancer Research Initiative are studying the combination of Genprex's REQORSA, which uses the TUSC2 tumor suppressor gene, with various ALK inhibitors.
  • Genprex believes this system allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.

Overcoming 'Otherness' in Scientific Research Commentary in Nature Human Behavior

Retrieved on: 
Friday, February 2, 2024

Dr. Delgado explains further, "True scientific excellence requires all voices, and varied experiences and perspectives.

Key Points: 
  • Dr. Delgado explains further, "True scientific excellence requires all voices, and varied experiences and perspectives.
  • To harness the full potential of our society, we must recognize and actively address the biases that 'otherness' introduces into scientific research."
  • The commentary highlights the detrimental impact of 'otherness' in scientific methodologies and outcomes, particularly in health-related research.
  • For the full commentary, please visit Nature Human Behavior: https://www.nature.com/articles/s41562-024-01821-y

Author and Health Equity Leader Daniel E. Dawes, J.D., to Keynote Inaugural Health Summit

Retrieved on: 
Thursday, January 18, 2024

A recognized leader in the health equity movement, Dawes is most known for for his best-selling books, “150 Years of Obamacare” and “The Political Determinants of Health.” He currently serves as the Senior Vice President, Global Health & Executive Director of the Global Health Equity Institute at Meharry Medical College.

Key Points: 
  • A recognized leader in the health equity movement, Dawes is most known for for his best-selling books, “150 Years of Obamacare” and “The Political Determinants of Health.” He currently serves as the Senior Vice President, Global Health & Executive Director of the Global Health Equity Institute at Meharry Medical College.
  • “Creating and investing in healthy communities touches every aspect of public health today.
  • This summit addresses those diverse intersections,” said TIP Executive Director Terri Burke.
  • For more information about schedules, accommodations and early-bird pricing — available through March 4 — visit https://immunizeusa.org/intersection-summit/ .

FREE ADMISSION ON KING DAY AT THE NATIONAL CIVIL RIGHTS MUSEUM

Retrieved on: 
Tuesday, January 9, 2024

Thanks to the generous support of FedEx, admission to the museum on King Day will be free for all guests.

Key Points: 
  • Thanks to the generous support of FedEx, admission to the museum on King Day will be free for all guests.
  • A portion of the King Day program will livestream on the museum’s website from 11:30-1:30 pm Central with reflections on Dr. King and the holiday with entertainment.
  • Several corporations and organizations have committed volunteers to serve at the museum on King Day.
  • For more information about King Day events and activities at the National Civil Rights Museum, visit kingday.org .

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

Retrieved on: 
Monday, November 13, 2023

TARRYTOWN, N.Y. and WASHINGTON, D.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (Society) today announced that Regeneron is increasing and extending its commitment as the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s largest high school science and engineering competition, with a total investment of approximately $34 million over a five-year period.

Key Points: 
  • Each year, over 175,000 students compete in the Society's 400 affiliated high school science fairs around the world.
  • Top winners earn the right to compete at Regeneron ISEF where nearly 1,600 finalists, half of whom are young female scientists, are judged in 22 different categories.
  • The renewed sponsorship builds on Regeneron and the Society's long-standing partnership to advance STEM education, including through Regeneron's $100 million, ten-year commitment to the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science and mathematics competition.
  • These high school science competitions play a pivotal role in directing high school students towards STEM careers.